RNAC

Company Overview — What Does Cartesian Therapeutics, Inc. Do?

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG. Cartesian Therapeutics, Inc. (RNAC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Carsten Brunn and employs approximately 64 people, headquartered in WATERTOWN, Maryland. With a market capitalization of $169M, RNAC is one of the notable companies in the Healthcare sector.

Cartesian Therapeutics, Inc. (RNAC) Stock Rating — Avoid (April 2026)

As of April 2026, Cartesian Therapeutics, Inc. receives a Avoid rating with a composite score of 19.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.RNAC ranks #4,415 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cartesian Therapeutics, Inc. ranks #830 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RNAC Stock Price and 52-Week Range

Cartesian Therapeutics, Inc. (RNAC) currently trades at $5.98. The stock lost $0.20 (3.2%) in the most recent trading session. The 52-week high for RNAC is $16.79, which means the stock is currently trading -64.4% from its annual peak. The 52-week low is $5.98, putting the stock 0.0% above its annual trough. Recent trading volume was 175K shares, suggesting relatively thin trading activity.

Is RNAC Overvalued or Undervalued? — Valuation Analysis

Cartesian Therapeutics, Inc. (RNAC) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 74.42x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cartesian Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cartesian Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Cartesian Therapeutics, Inc. (RNAC) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 273.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -20.9% versus the sector average of -33.1%.

On a margin basis, Cartesian Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -4627.8% (sector: -66.1%). Net profit margin stands at -2617.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -98.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RNAC Debt, Balance Sheet, and Financial Health

Cartesian Therapeutics, Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.65x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $143M.

RNAC has a beta of 2.07, meaning it is more volatile than the broader market — a $10,000 investment in RNAC would be expected to move 107.0% more than the S&P 500 on any given day. The stability factor score for Cartesian Therapeutics, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cartesian Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cartesian Therapeutics, Inc. reported revenue of $2M and earnings per share (EPS) of $-5.02. Net income for the quarter was $-62M. Gross margin was 100.0%. Operating income came in at $-82M.

In FY 2025, Cartesian Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-5.02. Net income for the quarter was $-130M. Revenue grew -92.8% year-over-year compared to FY 2024. Operating income came in at $-143M.

In Q3 2025, Cartesian Therapeutics, Inc. reported revenue of $452,000 and earnings per share (EPS) of $-1.38. Net income for the quarter was $-36M. Revenue grew 16.8% year-over-year compared to Q3 2024. Operating income came in at $-21M.

In Q2 2025, Cartesian Therapeutics, Inc. reported revenue of $298,000 and earnings per share (EPS) of $0.51. Net income for the quarter was $16M. Revenue grew -99.1% year-over-year compared to Q2 2024. Operating income came in at $-22M.

Over the past 8 quarters, Cartesian Therapeutics, Inc. has experienced revenue contraction from $33M to $2M. Investors analyzing RNAC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RNAC Dividend Yield and Income Analysis

Cartesian Therapeutics, Inc. (RNAC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RNAC Momentum and Technical Analysis Profile

Cartesian Therapeutics, Inc. (RNAC) has a momentum factor score of 20/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 39/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RNAC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cartesian Therapeutics, Inc. (RNAC) ranks #830 out of 838 stocks based on the Blank Capital composite score. This places RNAC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RNAC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RNAC vs S&P 500 (SPY) comparison to assess how Cartesian Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

RNAC Next Earnings Date

No upcoming earnings date has been announced for Cartesian Therapeutics, Inc. (RNAC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RNAC? — Investment Thesis Summary

The quantitative profile for Cartesian Therapeutics, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 20/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Cartesian Therapeutics, Inc. (RNAC) earns a Avoid rating with a composite score of 19.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RNAC stock.

Related Resources for RNAC Investors

Explore more research and tools: RNAC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RNAC head-to-head with peers: RNAC vs AZN, RNAC vs SLGL, RNAC vs VMD.